Pulmonary Arterial Hypertension and Response to Tadalafil - PHIRST

Description:

Sildenafil has been shown to be beneficial in patients with pulmonary arterial hypertension (PAH) in improving exercise capacity and hemodynamic parameters. However, there are no trials studying the role of sildenafil or other similar phosphodiesterase type-5 (PDE-5) inhibitors in patients with PAH who are already on the endothelin receptor antagonist bosentan. Moreover, sildenafil is a three times daily drug. The current study sought to investigate the role of tadalafil in patients with PAH, wi...